Sequential meta-analysis: an efficient decision-making tool

被引:42
作者
van der Tweel, Ingeborg [1 ]
Bollen, Casper [2 ]
机构
[1] Univ Med Ctr, Julius Ctr, Dept Biostat, Utrecht, Netherlands
[2] Univ Med Ctr, Pediat Intens Care Unit, Utrecht, Netherlands
关键词
RANDOMIZED CONTROLLED-TRIALS; COULD CLINICAL EQUIPOISE; CUMULATIVE METAANALYSIS; ITERATED LOGARITHM; CARDIAC-SURGERY; PRETERM INFANTS; VENTILATION; APROTININ; LAW;
D O I
10.1177/1740774509360994
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Background A cumulative meta-analysis of successive randomized controlled trials (RCTs) can be used to decide whether enough evidence has been obtained comparing a control and an intervention treatment or whether a new RCT should be initiated. In general, no adjustment is made for repeatedly testing the null hypothesis of treatment equivalence on cumulative data. Neither can the power of the statistical test be quantified. Recently, trial sequential analysis (TSA) was suggested to '... establish when firm evidence is reached in cumulative meta-analysis'. TSA is based on a-spending functions and necessitates a prior estimate of the total information size. Various information sizes were suggested. Purpose The aim of this study is to compare TSA with sequential meta-analysis (SMA) following Whitehead's boundaries approach. Methods We compare TSA and SMA by re-analysis of a number of published examples. Results Re-analysis of the examples shows that for an SMA: (1) no prior estimate for total information size is necessary and thus one set of boundaries suffices; (2) stopping a cumulative meta-analysis for futility is an option; (3) the power can be quantified; (4) point and interval estimates are adjusted for the multiple testing; and (5) gains in efficiency can be achieved, both for efficacy and for futility and thus ethical and economical benefits can be obtained. Limitations Estimates for between-trial variability are unstable for a small number of trials. The behavior of a newly proposed estimate should be subject of further investigation. Conclusion SMA is a useful tool to investigate the cumulative evidence from successive RCTs. Clinical Trials 2010; 7: 136-146. http://ctj.sagepub.com
引用
收藏
页码:136 / 146
页数:11
相关论文
共 34 条
[1]
[Anonymous], 1997, COCHRANE DB SYST REV
[2]
BARRINGTON KJ, 1999, COCHRANE DB SYST REV, V2
[3]
Uncertainty of the time of first significance in random effects cumulative meta-analysis [J].
Berkey, CS ;
Mosteller, F ;
Lau, J ;
Antman, EM .
CONTROLLED CLINICAL TRIALS, 1996, 17 (05) :357-371
[4]
Sequential meta-analysis of past clinical trials to determine the use of a new trial [J].
Bollen, Casper W. ;
Uiterwaal, Cuno S. P. M. ;
van Vught, Adrianus J. ;
van der Tweel, Ingeborg .
EPIDEMIOLOGY, 2006, 17 (06) :644-649
[5]
Brion LP., 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003665, DOI 10.1002/14651858.CD003665]
[6]
Bury RG, 2000, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858
[7]
Chalmers I, 2005, CLIN TRIALS, V2, P229
[8]
INTERIM ANALYSIS - THE ALPHA-SPENDING FUNCTION-APPROACH [J].
DEMETS, DL ;
LAN, KKG .
STATISTICS IN MEDICINE, 1994, 13 (13-14) :1341-1352
[9]
Random-effects model for meta-analysis of clinical trials: An update [J].
DerSimonian, Rebecca ;
Kacker, Raghu .
CONTEMPORARY CLINICAL TRIALS, 2007, 28 (02) :105-114
[10]
Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? [J].
Fergusson, D ;
Glass, KC ;
Hutton, B ;
Shapiro, S .
CLINICAL TRIALS, 2005, 2 (03) :218-229